年表作成・共有サービス - pastport

https://www.pharmasources.com/products/gel-clot-lyophilized-amebocyte-lysate-mu-253921.html

Global contract development and manufacturing organization (CDMO), Recipharm, is investing in a new facility in Uttarakhand, India, which will see its fill finish capacity increase to 1 billion sterile units per year.

The facility will be constructed on a greenfield site near Dehradun in Uttarakhand and is a joint project between Recipharm and the Sobti family.

The new site, which is designed for approval to supply the EU and U.S. is now ready to begin production following approval from the local authorities. It will be delivering ampoules, vials filled with liquid and powder, lyophilized vials, dental cartridges, and pre-filled syringes.

“This is a great milestone for our ongoing partnership with the Sobti family,” said Marc Funk, CEO, Recipharm. “From the new facility we’ll be able to provide customers with invaluable access to high quality sterile fill and finish capacity, which is in huge demand globally. A lot of hard work has gone in to ensuring the success of this project and we’re delighted to see it come to fruition.”

The new facility is the latest development in Recipharm’s partnership with the Sobti family which began in 2019 when Recipharm invested in Nichepharm.

Chetan Sobti and Nitin Sobti, co-founders of Nichepharm, said, “This partnership represents a real opportunity to take Nichepharm to the next level. The Sobti family is very pleased to be entering in the next stage of this partnership with Recipharm which will bring it access to new technologies, best in class account management and global standards of GMP compliance.”

The next step for the project will be to obtain authorization from the European authorities.

The facility will allow Recipharm to further increase its offering in sterile fill and finish services as it complements its three other sterile filling capabilities in France, Germany and Italy.